Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12738763 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kim DW, et al. (2003) RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17, 1382-94 12738763
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y9-p - PDK1 (human) ▲
Orthologous residues
PDK1 (human): Y9‑p, PDK1 iso4 (human): Y9‑p, PDK1 (mouse): Y9‑p, PDK1 (rat): Y9‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Ret (human) transfection of wild-type enzyme, phospho-antibody, microscopy-colocalization, transfection of inactive enzyme
 Comments:  RET/PTC
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
wortmannin no change compared to control
LY294002 no change compared to control
PP1 no change compared to control
N-alpha-tosyl-L-phenylalanyl chloromethyl ketone no change compared to control
rapamycin no change compared to control
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced
 Effect of modification (process):  transcription, altered
 Comments:  inhibits p53 promoter transcription

Y373-p - PDK1 (human) ▲
Orthologous residues
PDK1 (human): Y373‑p, PDK1 iso4 (human): Y246‑p, PDK1 (mouse): Y376‑p, PDK1 (rat): Y376‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase

Y376-p - PDK1 (human) ▲
Orthologous residues
PDK1 (human): Y376‑p, PDK1 iso4 (human): Y249‑p, PDK1 (mouse): Y379‑p, PDK1 (rat): Y379‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.